Weltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.

Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.

In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.

US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.

At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.

Clinicians at CHEST 2026 will see late-breaking COPD, asthma, pulmonary hypertension, and bronchoscopy data, plus exclusive expert interviews.